Glycominds improves personalized patient care
Glycominds, an innovative diagnostics company, develops and commercializes autoimmune and chronic inflammatory disease management tools and services with a distinctive focus on the Multiple Sclerosis market. Our proprietary tests allow physicians to help identify patients who have MS, and MS patients at a higher risk for more severe disease outcomes.
Glycominds current products include tests to help develop personalized therapy approaches for patients with Multiple Sclerosis and Crohn’s Disease. These tests are easy to administer and non-invasive.
Glycominds gMS® tests help physicians identify patients who have Multiple Sclerosis and which of these patients are likely to progress towards disability. These patients require more aggressive treatment and several new aggressive treatment options are becoming available to physicians.
Glycominds IBDX® tests help physicians identify patients who have Crohn’s Disease and which of the patients are at higher risk for bowel damages and surgery. These patients can be candiates for “top down” therapy with biologics.
Glycominds Laboratory Services is a CLIA-certified laboratory operated in Simi Valley, California, USA by Glycominds Inc.
Contact: Glycominds Inc.
4685 Runway St., Ste. J
Simi Valley, CA 93063
(805) 791-2094 Office
(805) 791-2086 Fax
CLIA Certification Number: 05D2010838
The laboratory offers novel gMS® testing for the diagnosis and prognosis of Multiple Sclerosis patients. Glycominds works with physicians to arrange for patient testing via a secure and convenient program in conjunction with phlebotomist services, which arrange for patients to have their blood samples collected at a convenient time and place.
US Laboratory Clients Performing Glycominds IBDX® technology for Crohn’s Disease
LabCorp - Laboratory Corporation of America
Scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology.
ARUP Laboratories, Inc.
A national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development.
Innovative Research for Personalized Treatment
For more than 10 years, Glycominds has been a leading groundbreaker in Multiple Sclerosis research, offering the only serum biomarker tests on the market for MS. Our laboratories produce results from a strong and proprietary technology platform, providing answers to physicians that allow many patients to benefit from personalized control over their diagnosis and/or progression of their disease.
Center of Excellence for Multiple Sclerosis
Glycominds is in a unique position to answer previously unmet needs for MS. Our focused research, reliability and quality are unparalled in the Medical and Health biotechnology market. We present a high value proposition, highlighting our clinically proven tests, dominant health care economics cost-effectiveness and overall saving models, a strong Leadership Team and an experienced Board of Directors.
We commenced marketing gMS® tests by 2011 through a subsidiary in the US, Glycominds Inc. These tests are in growing demand, with more than 1,000 tests resulted to date, and we are answering that increasing need with rapid ramp-up in the US.
Advancing Science through Strategic Agreements
We have in-network agreements with leading PPO providers, covering more than 50 million policy holders. This allows us to focus our sales and marketing activity in a proactive way by targeting territories that boost our consistently improving reimbursement capabilities.